Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Gen Dent ; 72(3): 74-77, 2024.
Article in English | MEDLINE | ID: mdl-38640011

ABSTRACT

Human papillomavirus (HPV) is associated with both benign and malignant disorders, such as genital warts and a variety of cancers, including oropharyngeal squamous cell carcinomas (OPSCCs). The current 9-valent HPV vaccine (Gardasil 9) protects against high-risk strains that have been shown to cause OPSCC, and widespread vaccination should reduce the rate of all HPV-associated cancers. HPV-related OPSCCs differ from non-HPV-related OPSCCs in their clinical presentations and responsiveness to treatment. To provide oral healthcare providers with a basis for effective com-munication with patients, this article will examine the evolution of the HPV vaccination schedule and the role of the HPV vaccine in the prevention of OPSCCs.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Oropharyngeal Neoplasms , Papillomavirus Infections , Papillomavirus Vaccines , Humans , Human Papillomavirus Viruses , Papillomavirus Infections/complications , Papillomavirus Infections/prevention & control , Carcinoma, Squamous Cell/prevention & control , Carcinoma, Squamous Cell/pathology , Oropharyngeal Neoplasms/prevention & control , Oropharyngeal Neoplasms/pathology , Squamous Cell Carcinoma of Head and Neck/complications , Head and Neck Neoplasms/complications , Papillomavirus Vaccines/therapeutic use
2.
Front Endocrinol (Lausanne) ; 14: 1132743, 2023.
Article in English | MEDLINE | ID: mdl-37124751

ABSTRACT

Background: In women, placental corticotropin releasing hormone (CRH) can be detected in maternal blood throughout pregnancy and is important in the regulation of the timing of parturition. However, its role in other mammalian species is unclear. In fact, very little is known about the presence and localization of CRH in placentas other than human. In this study we report for the first time the presence of CRH in feline placenta and maternal serum. Methods: Presence of CRH mRNA and protein was assessed using RT-PCR and Western blot, respectively, in at term domestic cat placentas opportunistically obtained at a local animal shelter and spay clinic. In addition, CRH localization within the placenta was demonstrated via immunohistochemistry. Finally, presence of CRH in maternal blood from early (¾21 days) and mid (25-35 days) stages of pregnancy was investigated by ELISA. Results: CRH mRNA and protein were detected in feline placentas, and localized to larger decidual cells and fetal trophoblast cells, including the binucleate cells. CRH was detectable in maternal blood collected from early-stage pregnancies, and amounts significantly increased in mid-gestation samples. Conclusion: This is the first report on the presence and localization of CRH in the feline placenta, and its increase in maternal serum during the first half of pregnancy. These data lay the foundation for future studies to determine if CRH can be used as potential novel marker for early pregnancy diagnosis, determination, and monitoring in felids, and could greatly increase efficiency and success in zoo breeding programs utilizing artificial reproductive technologies for endangered feline species.


Subject(s)
Corticotropin-Releasing Hormone , Placenta , Animals , Cats , Placenta/chemistry , Corticotropin-Releasing Hormone/analysis , Corticotropin-Releasing Hormone/blood , Corticotropin-Releasing Hormone/genetics , Female , Pregnancy/blood , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay , RNA, Messenger/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...